Good Governance for Medicines (GGM) Overview
The GGM programme was launched in 2004 with the goal of contributing to health systems strengthening and preventing corruption by promoting good governance in the pharmaceutical sector.
World Health Assembly 66 Side Event 20 May 2013: Good governance in the pharmaceutical sector the case of Thailand and Malawi
The experiences from the Good Governance for Medicines programme in Thailand and Malawi was shared as well as the findings and the recommendations from the evaluation. The event was held at 18:00 in room VII.
- To raise awareness on the impact of corruption in the pharmaceutical sector and bring this to the national health policy agenda
- To increase transparency and accountability in medicine regulatory and supply management systems
- To promote individual and institutional integrity in the pharmaceutical sector
- To institutionalize good governance in pharmaceutical systems by building national capacity and leadership.
GGM programme approach
The concept underlying the GGM approach is that by supporting policy-makers and national officials to understand where the strengths and weaknesses lie in national pharmaceutical systems, appropriate interventions can be developed and applied.
With the support of the German Federal Ministry for Economic Cooperation and Development and the Government of Kuwait the programme has grown to include 36 participating countries.
- Measuring Transparency in the Public Pharmaceutical Sector Assessment Instrument
- WHO Model Framework for Good Governance in the Pharmaceutical Sector Updated version